On November 13th, Forbes released the list of 2024 China's Top 50 Most Innovative Companies, and Biokin Pharmaceutical made the list due to its innovative leadership in the field of innovative biopharmaceuticals.

Biokin Pharmaceutical is committed to achieving breakthrough efficacy through groundbreaking innovations. It has developed world-leading ADCs and antibody drugs, and has established a globally leading innovative ADC drug research and development platform (HIRE-ADC platform), a globally leading innovative multi-specific antibody drug research and development platform (GNC platform), and a specificity-enhanced bispecific antibody platform (SEBA platform). As of August 24, 2024, the company has successfully developed 3 Phase III clinical assets (including 2 ADC drugs and 1 bispecific antibody drug), 10 early-stage core clinical assets (including 5 ADC drugs, 4 GNC drugs, and 1 bispecific antibody drug), as well as a series of preclinical innovative drug projects based on the aforementioned research and development platforms.